

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAREPTA THERAPEUTICS, INC.,

Petitioner

v.

Genzyme Corporation,

Patent Owner

U.S. Patent No. 12,298,313

“Methods for Detecting AAV”

IPR2026-00166

PETITIONER’S *SOTERA* STIPULATION

Petitioner hereby stipulates that, if the Board institutes and maintains *inter partes* review in this proceeding, IPR2026-00166, and institution is not subsequently vacated, or the IPR otherwise terminated without a Final Written Decision, Petitioner will not pursue in the parallel litigation, *Genzyme Corp. v. Sarepta Therapeutics, Inc. et al.*, C.A. No. 24-cv-00882-RGA (D. Del.), (1) the specific grounds raised in the Petition, (2) any grounds of invalidity arising under U.S.C. § 102 or § 103 involving patent or printed publication prior art that could have reasonably been raised before the Board with respect to U.S. Patent No. 12,298,313, or (3) any ground based on a combination of system prior art and the references asserted as part of a ground raised in the instituted IPR with respect to U.S. Patent No. 12,298,313.¹

¹ On October 17, 2025, the United States Patent and Trademark Office issued a Notice of Proposed Rulemaking proposing that “*inter partes* review shall not be instituted or maintained unless each petitioner files a stipulation with the Board and any other tribunal where it is litigating, or later litigates regarding the challenged patent, stating that if a trial is instituted, the petitioner and any real party in interest or privy of the petitioner will not raise grounds of invalidity or unpatentability with respect to the challenged patent under 35 U.S.C. 102 or 103 in any other proceeding.” 90 Fed. Reg. 48341, <https://www.govinfo.gov/content/pkg/FR-2025-10-17/pdf/2025-19580.pdf>. In the event these proposed rule changes are implemented, Petitioner reserves the right to modify its stipulation to conform to the regulations as ultimately implemented.

Date: December 30, 2025

/s/ Robert B. Wilson

Robert B. Wilson
Registration No. 45,227
Quinn Emanuel Urquhart & Sullivan,
LLP
295 Fifth Avenue, 9th Floor
New York, New York 10016
Tel.: 212-849-7000
Fax: 212-849-7100

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6, I hereby certify that on December 30, 2025
the foregoing document was served via email on the following counsel of record:

amanda.antons@dechert.com
khelm@dechert.com
blaine.hackman@dechert.com

/s/ Robert B. Wilson

Robert B. Wilson
Registration No. 45,227
Quinn Emanuel Urquhart & Sullivan,
LLP
295 Fifth Avenue, 9th Floor
New York, New York 10016
Tel.: 212-849-7000
Fax: 212-849-7100